HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Preprint of results from animal study shows restriction of tumor growth in...
Patent provides intellectual property protection until December 2040PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more...
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, March 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a...
SILVER SPRING, Md. and IRVINE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company...
- Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO - - Matthew...
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm...
2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2...
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality LAWRENCEVILLE, N.J.,...
- In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped transcripts in biceps; a...
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and...
Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial ExecutionMORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos...
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate...
Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S....
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
Company Unveils EVOLVE-105 Program, A Best-in-Class CD20xCD3 Multispecific Antibody Designed to Concurrently Drive CD2 Costimulation to Improve the Treatment of...
ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company...
CHICAGO and TORONTO, March 21, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),...
New features provide real-time updates on the impact medical affairs teams are having on the HCP and HCO community to...
The Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) --...